Lung Cancer
Papers 10000
1 page of 1,000 pages (10k results)
#1Fang Wang (SYSU: Sun Yat-sen University)H-Index: 11
#2Shao-Yan Xi (SYSU: Sun Yat-sen University)
Last. Hai-Yun Wang (Guangzhou Medical University)
view all 10 authors...
OBJECTIVES Primary pulmonary salivary gland-type tumors (PSGTs) mainly comprise of mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC), which are rare and molecularly poorly understood. This study aimed to profile the molecular alterations of PSGTs via targeted next-generation sequencing (NGS). MATERIAL AND METHODS Immunohistochemistry was used to screen PSGTs in 32 patients and MAML2 and MYB rearrangements were detected using fluorescence in situ hybridization. 1021-Genepanel of t...
#1Kiyotaka YohH-Index: 27
#2Shingo MatsumotoH-Index: 36
Last. Atsushi NakamuraH-Index: 11
view all 17 authors...
Abstract null null Objectives null Immune checkpoint inhibitors (ICIs) have proven to be effective treatment for lung cancer. However, a precise predictive immuno-oncology biomarker is still under development. We investigated the associations among PD-L1 expression, tumor mutational burden (TMB), and oncogenic driver alterations in advanced non-small cell lung cancer (NSCLC) patients treated with ICIs. null null null Materials and methods null This multicenter cohort study included 1017 lung can...
#1Na Zhou (Qingdao University)H-Index: 5
#2Man Jiang (Qingdao University)H-Index: 6
Last. Xiaochun Zhang (Qingdao University)H-Index: 11
view all 0 authors...
Abstract null null Objectives null Combined therapy should be invested for those patients who are refractory to first-line therapy. Anti-angiogenic agents could enhance tumor immunity response. We designed a phase IB clinical trial and analyzed the effectiveness and safety of anlotinib combined with PD-1inhibitors Camrelizumab for multi-line pretreated and failed advanced NSCLC to explore the synergistic effect of anti-angiogenic agents and immunotherapy. null null null Methods null All enrolled...
Abstract null null Objectives null Primary lung carcinomas are very rare paediatric tumours with an incidence of null null null null Material and methods null Between 2009 and 2019, twelve children and adolescents with lung carcinoma were identified in the prospective German registry for rare paediatric tumours (STEP). Data were analysed for histopathological entities, symptoms, diagnostics, therapy, clinical course and outcome. null null null Results null Mucoepidermoid carcinoma (MEC) was the ...
#1Carol C. Cheung (UHN: University Health Network)H-Index: 16
#2Adam C. Smith (UHN: University Health Network)H-Index: 25
Last. Doha Itani (MCW: Medical College of Wisconsin)H-Index: 9
view all 29 authors...
Abstract null null Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that all advanced stage non-squamous NSCLC patients be also tested for ROS1 gene rearrangements. Several studies have suggested that ROS1 immunohistochemistry (IHC) using the D4D6 antibody may be used to screen for ROS1 fusion positive lung cancers, with as...
#1Di Liu (Fudan University)H-Index: 7
#2Xinyan Xu (Fudan University)H-Index: 5
Last. Min Fan (Fudan University)H-Index: 15
view all 5 authors...
#1Parth Shah (Dartmouth College)
#2Jacob Sands (Harvard University)H-Index: 6
Last. Nicola NormannoH-Index: 74
view all 3 authors...
Abstract null null Epidermal growth factor receptor (EGFR) mutation testing in advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past decade, largely triggered by the introduction of the targeted EGFR tyrosine kinase inhibitors (TKIs). Initially used to detect common EGFR mutations and determine the most appropriate first-line therapy at diagnosis, testing methodologies have expanded to test for multiple mutations at multiple time points throughout the disease course. Here...
#1Charles Vauchier (University of Paris)
#2Johan Pluvy (University of Paris)H-Index: 1
Last. Gérard Zalcman (Curie Institute)H-Index: 9
view all 8 authors...
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a major breakthrough in lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS), the availability of sensitivity markers to immune-checkpoint inhibitors (ICI) would be useful for attending physicians and assist them in their decision-making process. Deficient mismatch repair (dMMR) can lead to high microsatellite instability (MSI-H) and coexist with mutations in polymer...
#1Christi M.J. Steendam (EUR: Erasmus University Rotterdam)H-Index: 3
#2Robert Peric (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Stijn L.W. Koolen (EUR: Erasmus University Rotterdam)H-Index: 13
view all 15 authors...
Abstract null null Background null Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib in relapsed metastasized non-squamous (NSQ) non-small cell lung cancer (NSCLC). null null null Methods null Patients with relapsed Epidermal Growth Factor Receptor (EGFR) wild type (WT) NSQ-NSCLC were randomized 1:1 to docetaxel 75 mg/m2 intravenously ...
#1Keiju AokageH-Index: 24
#2Tomohiro MiyoshiH-Index: 14
Last. Masahiro TsuboiH-Index: 49
view all 8 authors...
Abstract null null Objectives null The ADAURA demonstrated the efficacy of osimertinib as adjuvant therapy in patients with resected stage IB-IIIA adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations. However, it is controversial whether adjuvant therapy should be applied to all these patients because of their heterogeneities. This study aimed to examine the influence of GGO and EGFR mutations on the prognosis and to identify optimal targets for the development of periopera...
Top fields of study
Lung cancer
Cancer research